Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, November 10, 2025 at 8:30 a.m. EST to report third quarter 2025 financial results and provide operational updates.
Participants can register in advance and join the call via the North America toll-free number 1-800-836-8184. A live webcast will be available under Events and Presentations in the Investors section at ir.adctherapeutics.com. It is recommended to join 10 minutes early. The archived webcast will remain available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, November 10, 2025 at 8:30 a.m. EST to report third quarter 2025 financial results and provide operational updates.
Participants can register in advance and join the call via the North America toll-free number 1-800-836-8184. A live webcast will be available under Events and Presentations in the Investors section at ir.adctherapeutics.com. It is recommended to join 10 minutes early. The archived webcast will remain available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.
Schedule:
- Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
- Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
- Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)
Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.
ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.
Schedule:
- Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
- Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
- Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)
Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.
ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.
The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.
ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.
The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
